功能遗传学揭示了delta阿片类受体对2型糖尿病和β细胞功能贡献的作用
Sarah Meulebrouck1, Judith Merrheim1, Gurvan Queniat1
1Université de Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France.
德尔塔阿片类受体 (DOP) 基因影响2型糖尿病风险. 与DOP功能相关的变异影响脂肪和血糖,表明DOP是糖尿病的潜在治疗标.
科学领域:
- 遗传学和内分泌学
- 代谢障碍 研究 研究 代谢障碍
背景情况:
- 阿片类药物的使用会影响新陈代谢的平衡,但潜在的机制尚不清楚.
- 编码三角形阿片类受体 (DOP) 的 OPRD1 基因与代谢调节有关.
研究的目的:
- 研究OPRD1基因及其编码的三角形阿片类受体 (DOP) 在2型糖尿病中的作用.
- 探索DOP作为代谢障碍的潜在治疗点.
主要方法:
- 大规模的OPRD1基因测序.
- 在体外分析OPRD1变异及其与代谢表型的关联.
- 研究人类小岛和β细胞中的DOP表达.
- 用RNA测序来识别由DOP对抗性调节的途径.
主要成果:
- 功能丧失的OPRD1变体与更高的脂肪和降低高血糖风险相关.
- 功能获取的OPRD1变体与较低的脂肪和增加2型糖尿病风险相关.
- DOP在人类小岛和β细胞中表达,在2型糖尿病中表达率下降.
- 抑制DOP可以增强胰岛素分泌,调节神经生长因子,生理时钟和核受体通路.
结论:
- 达尔塔阿片类受体 (DOP) 在阿片类药物使用和代谢平衡之间的相互作用中发挥着重要作用.
- OPRD1变种影响2型糖尿病风险和肥胖.
- DOP对抗性为管理2型糖尿病提供了一个有前途的治疗策略.
更多相关视频
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
相关概念视频
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Opioid Receptors: Overview
